Home Cart Sign in  
Chemical Structure| 1187595-84-1 Chemical Structure| 1187595-84-1

Structure of Baricitinib phosphate
CAS No.: 1187595-84-1

Chemical Structure| 1187595-84-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Baricitinib phosphate (LY3009104 phosphate; INCB028050 phosphate) is a selective, orally bioavailable JAK1/JAK2 inhibitor with IC50 values of 5.9 nM and 5.7 nM, respectively.

Synonyms: INCB028050 phosphate; LY3009104 phosphate

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Fofie, Christian Kuete ; Granja-Vazquez, Rafael ; Truong, Vincent ; Walsh, Patrick ; Price, Theodore ; Biswas, Swati , et al.

Abstract: Chronic pain is a global health issue, yet effective treatments remain limited due to poor preclinical-to-human translation. To address this, we developed a high-content screening (HCS) platform using hiPSC-derived nociceptors to identify analgesics targeting the peripheral nervous system. These cells, cultured on multi-well microelectrode arrays, achieved nearly 100% active electrodes by week 2, maintaining stable activity for at least 2 weeks. After 28 days, we assessed drug effects on neuronal activity, achieving strong assay performance (robust Z′ > 0.5). Pharmacological tests confirmed responses to key analgesic targets, including ion channels (Nav, Cav, Kv, and TRPV1), neurotransmitter receptors (AMPAR and GABA-R), and kinase inhibitors (tyrosine and JAK1/2). Transcriptomic analysis validated target expression, though levels differed from primary human DRG cells. The platform was used to screen over 700 natural compounds, demonstrating its potential for analgesic discovery. This HCS platform facilitates the rapid discovery of uncharacterized analgesics, reducing preclinical-to-human translation failure.

Purchased from AmBeed: ; ; ;

Alternative Products

Product Details of Baricitinib phosphate

CAS No. :1187595-84-1
Formula : C16H20N7O6PS
M.W : 469.41
SMILES Code : N#CCC1(N2N=CC(C3=C4C(NC=C4)=NC=N3)=C2)CN(S(=O)(CC)=O)C1.O=P(O)(O)O
Synonyms :
INCB028050 phosphate; LY3009104 phosphate
MDL No. :MFCD25976707
InChI Key :FBPOWTFFUBBKBB-UHFFFAOYSA-N
Pubchem ID :44231848

Safety of Baricitinib phosphate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Baricitinib phosphate

epigenetics
RTK
JAK-STAT

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Peripheral blood mononuclear cells 2 to 10,000 nM 1 hour To evaluate the differences among JAK inhibitors at the cellular level, measure phosphorylated STAT levels following cytokine stimulation, and calculate IC50 values. PMC6679539
IμMortalized podocytes 1 µM 2 days To investigate whether Baricitinib could restore the cytoskeletal structures of podocytes under inflaμMatory stimulation, results showed that Baricitinib could recover the cytoskeletal structures. PMC8419414
Primary podocytes 10 ng/mL IL-6 24 hours To investigate whether Baricitinib could ameliorate morphological abnormalities of podocytes under IL-6 stimulation, results showed that Baricitinib could ameliorate the abnormalities. PMC8419414
HGPS SKPs 1 µM 14 days Baricitinib alone or in combination with FTI improved the differentiation of HGPS SKPs into adipocytes and increased lipid droplet formation. PMC10216179
FPLD2 SKPs 1 µM 14 days Baricitinib alone or in combination with FTI improved the differentiation of FPLD2 SKPs into adipocytes and increased lipid droplet formation. PMC10216179
MADB SKPs 1 µM 14 days Baricitinib alone or in combination with FTI improved the differentiation of MADB SKPs into adipocytes and increased lipid droplet formation. PMC10216179
Neuro-2a cells 400 ng/mL 8 hours To investigate the effects of Baricitinib on the IL-6/JAK/STAT3 pathway and Csf1 expression in neuronal cells. Results showed that Baricitinib significantly suppressed the expression of Socs3, Il6, and Csf1 induced by IL-6 and IL-6R. PMC11179219

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Rhesus macaques SARS-CoV-2 infection model Oral 0.5mg Once daily for 12 months Baricitinib treatment reduced lung pathology, inflammatory cell infiltration, and neutrophil NETosis activity in SARS-CoV-2-infected rhesus macaques while preserving antiviral responses. PMC7654323
Mice Systemic lupus erythematosus model Gavage 0.32 mg/kg Single injection, lasting 6 hours To investigate whether Baricitinib could ameliorate systemic lupus erythematosus-like phenotypes, results showed that Baricitinib could significantly improve splenomegaly, lymphadenopathy, proteinuria, and modulate immune cell populations. PMC8419414
Mice Fully major histocompatibility mismatched skin and heart transplant models Subcutaneous injection 4 mg Once daily for 8-9 days Baricitinib combined with cyclosporine A (CsA) preserved fully major histocompatibility mismatched skin grafts for the entirety of a 111-day experimental period. In a fully major histocompatibility mismatched heart allograft model, baricitinib plus CsA prevented graft rejection for the entire 28-day treatment period compared with 9 days in controls. PMC10511772
DBA/1JJmsSlc mice Collagen antibody-induced arthritis (CAIA) model Oral 400 mg Daily for 111 days To investigate the effects of Baricitinib on alleviating inflammatory and neuropathic pain in CAIA model mice. Results showed that Baricitinib significantly improved arthritis-related pain and reduced the proliferation of microglia and astrocytes in the spinal cord by suppressing the IL-6/JAK/STAT3 pathway and CSF-1 expression. PMC11179219

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.13mL

0.43mL

0.21mL

10.65mL

2.13mL

1.07mL

21.30mL

4.26mL

2.13mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories